Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells-Reference-Cited by-同舟云学术

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Published:2024-06-21 Issue:8 Volume:38 Page:1825-1830
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Chatain Nicolas^ORCID,Baumeister Julian,Szymanski de Toledo Marcelo A.,Wong Dickson W. L.,Gupta Siddharth,Pannen Kristina,Junge Bärbel,Brümmendorf Tim H.^ORCID,Boor Peter^ORCID,Koschmieder Steffen^ORCID

Funder

Novartis | Novartis Pharma

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02320-9.pdf

Reference20 articles.

1. Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129:1595–606.

2. Saleh K, Fernandez A, Pasquier F. Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers. 2022;14:374–7.

3. Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, et al. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL: a Children’s Oncology Group (COG) study. Br J Haematol. 2012;157:507–10.

4. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–34.

5. Hofmann W-K, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102:659–61.